The gold standard for the diagnosis of G6PD deficiency is a quantitative assay using spectrophotometry, although novel point‐of‐care devices for quantitative assessment have recently been validated and marketed.11, 12 Qualitative tests include the fluorescent spot test and point‐of‐care rapid diagnostic tests (RDTs) using lateral flow technology, such as the CareStart G6PD RDT (Access Bio). The gene discussed is G6PD; the disease is G6PD deficiency.